MTE #2: New Frontiers in Targeting Alcohol Use and Liver Disease—Fibroblast Growth Factor 21 and Glucagon-like Peptide-1 Receptor Agonists (Ticketed)

Nov 06 2026

Convention Center: Room 1B

7:00 AM - 7:45 AM

Ticketed Event

CE Credits

World Class Speakers

Suthat Liangpunsakul

Discussion Leader

Cynthia L. Hsu

Discussion Leader

Description

Join topic experts for this intriguing session that explores the emerging therapeutic landscape for treating alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). Speakers focus specifically on fibroblast growth factor 21 (FGF21) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the context of AUD and ALD. Presenters also explore future translational research questions involving FGF21 and GLP-1 RAs.

Objectives

Review the neuroendocrine and liver-specific mechanisms underlying fibroblast growth factor 21 (FGF21) effects.
Discuss the preclinical and clinical evidence demonstrating how glucagon-like peptide-1 receptor agonist (GLP-1 RA) signaling modulates central reward and stress pathways involved in alcohol-seeking behavior, while also exerting peripheral metabolic, anti-inflammatory, and hepatoprotective effects.
Describe future translational research questions involving FGF21 and GLP-1 RAs.